Abstract:Diabetes mellitus (DM) is a common metabolic disease that poses a severe threat to human health. Despite a range of therapeutic approaches, there remains a lack of effective and safe therapies with the existing drugs. Therefore, there is an urgent need to develop novel, effective, and safe therapeutic strategies for DM. Free fatty acid receptor 4 (FFAR4), also known as GPR120, is a member of the G protein-coupled receptor family, which has received considerable attention as an attractive new therapeutic target for treating DM. In the present study, based on the structure of TUG-891, which has excellent activity and selectivity, a series of novel FFAR4 agonists was designed by replacing the phenylpropanoic acid β position carbon atom with an oxygen atom, while replacing the linking oxymethylene with an amide-linking group. The target compounds were evaluated for FFAR4 agonistic activity, and the preferred compounds were evaluated for selectivity, oral glucose tolerance in normal ICR mice, antidiabetic activity in diet-induced obese (DIO) mice, pharmacokinetic properties in ICR mice and molecular modeling studies. The results showed that compound 10f possessed excellent FFAR4 agonistic activity and selectivity, significantly improved glucose tolerance in normal ICR mice, lowered blood glucose and promoted insulin secretion in a dose-dependent manner in DIO mice, and showed favorable pharmacokinetic properties. These results indicate that compound 10f may be a promising compound that deserves further structure–activity relationship and pharmacological studies for the development of antidiabetic drugs.

Novel Phenoxyalkanoic Acid Derivatives as Free Fatty Acid Receptor 4 Agonists for Treating Type 2 Diabetes Mellitus

Synthesis and Biological Evaluation of Phenoxyacetic Acid Derivatives As Novel Free Fatty Acid Receptor 1 Agonists.

Design, Synthesis and Biological Activity of Phenoxyacetic Acid Derivatives As Novel Free Fatty Acid Receptor 1 Agonists.

Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development.

Design, Synthesis and Structure-Activity Relationship Studies of Novel Phenoxyacetamide-Based Free Fatty Acid Receptor 1 Agonists for the Treatment of Type 2 Diabetes

Discovery of Phenylsulfonyl Acetic Acid Derivatives with Improved Efficacy and Safety As Potent Free Fatty Acid Receptor 1 Agonists for the Treatment of Type 2 Diabetes

Design, Synthesis and Structure-Activity Relationship Studies of New Thiazole-Based Free Fatty Acid Receptor 1 Agonists for the Treatment of Type 2 Diabetes

Design, Synthesis and Structure-Activity Relationship Studies of Novel Free Fatty Acid Receptor 1 Agonists Bearing Amide Linker.

Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold

Free Fatty Acid Receptor 1 (FFAR1) As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges

Design, Synthesis, and Biological Evaluation of Novel Pan Agonists of FFA1, PPARγ and PPARδ.

Design, Synthesis, and Biological Evaluations of Phenylpropiolic Acid Derivatives As Novel GPR40 Agonists

Design, Synthesis, and Biological Evaluation of Deuterated Phenylpropionic Acid Derivatives As Potent and Long-Acting Free Fatty Acid Receptor 1 Agonists.

Design, Synthesis, and Biological Evaluation of Novel Dual FFA1 (gpr40)/pparδ Agonists As Potential Anti-Diabetic Agents.

Discovery of Novel Free Fatty Acid Receptor 1 Agonists Bearing Triazole Core Via Click Chemistry

Design, Synthesis and Biological Activity of Deuterium-Based FFA1 Agonists with Improved Pharmacokinetic Profiles

Discovery of First-in-class Thiazole-Based Dual FFA1/PPARδ Agonists As Potential Anti-Diabetic Agents

Design, Synthesis, and Biological Evaluation of Novel FFA1 Partial Agonists Bearing Oxime Ether Scaffold

Synthesis and evaluation of 3-(4-(phenoxymethyl)phenyl)propanoic acid and N-phenylbenzenesulfonamide derivatives as FFA4 agonists.

Discovery of Novel Pyrrole-Based Scaffold As Potent and Orally Bioavailable Free Fatty Acid Receptor 1 Agonists for the Treatment of Type 2 Diabetes

Discovery of a novel oxime ether scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists